Quick Answer
Aligos Therapeutics, Inc. reported Net Income of -$24.19 million for fiscal year 2025.
Aligos Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$24.19M | +81.6% |
| 2024 | -$131.21M | -49.6% |
| 2023 | -$87.68M | +8.7% |
| 2022 | -$96.05M | +25.2% |
| 2021 | -$128.33M | -18.2% |
| 2020 | -$108.54M | -107.7% |
| 2019 | -$52.26M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$31.54M | -63.8% | -98.8% |
| June 30, 2025 | -$15.86M | -413.4% | -136.8% |
| March 31, 2025 | $43.09M | +223.6% | +323.7% |
| September 30, 2024 | -$19.26M | -6.8% | -480.5% |
| June 30, 2024 | $5.06M | +126.9% | +114.5% |
| March 31, 2024 | -$34.86M | -51.9% | -93.2% |
| September 30, 2023 | -$18.04M | +3.1% | +4.0% |
| June 30, 2023 | -$18.79M | +5.7% | +18.1% |
- Aligos Therapeutics, Inc. showed an increase of +81.6% in Net Income compared to the prior fiscal year.
- Over the 2019–2025 period, Aligos Therapeutics, Inc.’s net income has grown by 53.7% (from -$52.26 million to -$24.19 million).
- The most recent figure is from Aligos Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: